Here are relevant reports on : recombinant-therapies-advanced-technologies-and-global-market
-
North America Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030
The North America vaccines market, valued at US$25.95 billion in 2024, stood at US$25.29 billion in 2025 and is projected to advance at a resilient CAGR of 7.1% from 2025 to 2030, culminating in a forecasted valuation of US$35.68 billion by the end of the period. The vaccines market is growing rapidly, driven by swift global vaccine development and commercialization, higher rates of infectious diseases necessitating preventive vaccines, expanded immunization initiatives, innovations in vaccine technology, and increased government funding and investments for novel vaccines against diverse diseases.
- Published: October 2026
- Price: $ 4950
- TOC Available:
-
Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023
The global viral clearance market is projected to reach USD 724.5 million by 2023, growing at a CAGR of 21.7%. The key players in the global viral clearance market are Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).
- Published: September 2018
- Price: $ 4950
- TOC Available:
-
Vaccines Market Size by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, mRNA), Type (Multivalent, Monovalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, Rotavirus, RSV, HPV, Polio), ROA (IM, SC, Oral), Competition - Global Forecast to 2031
The global vaccines market (excluding COVID-19) is projected to reach USD 71.14 billion by 2031, growing at a CAGR of 5.0% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Veterinary Vaccines Market by Type (Porcine, Poultry, Bovine, Ruminant, Canine, Feline, Aquaculture), Technology (Live Attenuated, Inactivated, Toxoid, Recombinant), Route of Administration (Subcutaneous, Oral), End User - Global Forecast to 2031
The global veterinary vaccines market is projected to reach USD 18.46 billion by 2031, growing at a CAGR of 7.2% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032
The global cancer vaccines market, valued at US$9.70 billion in 2023, stood at US$9.84 billion in 2024 and is projected to advance at a resilient CAGR of 5.4% from 2024 to 2032, culminating in a forecasted valuation of US$15.00 billion by the end of the period. The cancer vaccines market is growing rapidly, fueled by rising prevalence of cancer, technological advancements in immunotherapy, and increasing adoption of preventive healthcare across the globe.
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Global Albumin Market, by Product (Human Serum Albumin, Bovine Albumin, Recombinant Serum Albumin) by Application (Therapeutic, Drug Delivery, Culture Media, Vaccine Ingredient) by Region - Forecast to 2022
The global albumin market is projected to grow at a CAGR of around 6% during the forecast period (2017-2022). Factors such as the high demand of albumin in R&D activities, rising non-therapeutic application of albumin, development of plant based albumin, rising production of immunoglobulins, and rise in plasma collection are driving the market. However, the stringent regulations, limited reimbursement, and irrational uses and adverse effects associated with albumin are the factors restraining the growth of this market.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Respiratory Syncytial Virus (RSV) Vaccines Market by Technology (Recombinant, Inactivated & Subunit, Others), Type (Monovalent, Multivalent), End User (Pediatric, Adult) & Region – Global Forecast to 2030
The global Respiratory Syncytial Virus (RSV) Vaccines market, valued at US$1.53 billion in 2024, stood at US$1.60 billion in 2025 and is projected to advance at a resilient CAGR of -4.9% from 2025 to 2030, culminating in a forecasted valuation of US$1.24 billion by the end of the period. Growth is driven by the high burden of RSV among infants and older adults.
- Published: October 2026
- Price: $ 4950
- TOC Available:
-
Asia Pacific Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030
The Asia Pacific Vaccines market, valued at USD 9.46 billion in 2024, stood at USD 9.89 billion in 2025 and is projected to advance at a resilient CAGR of 9.0% from 2025 to 2030, culminating in a forecasted valuation of USD14.57 billion by the end of the period. The market is expanding quickly, driven by a rise in vaccine development and commercialization, heightened infectious disease rates, and the extensive use of preventive vaccines.
- Published: October 2026
- Price: $ 4950
- TOC Available:
-
Research Use (RUO) Recombinant Protein Market by Product (Cytokines, Growth Factors), Formulation (Lyophilized, Liquid), Species (Human, Mouse), Host (Mammalian, Yeast), Application (Cell Culture), End User, Competition, Region - Global Forecast to 2031
The global research use recombinant protein market is projected to reach USD 1.55 billion by 2031, growing at a CAGR of 7.0% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Europe Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, RSV), Route of Administration (IM, SC, Oral) - Forecast to 2030
The Europe vaccines market, valued at US$10.53 billion in 2024, stood at US$9.97 billion in 2025 and is projected to advance at a resilient CAGR of 6.6% from 2025 to 2030, culminating in a forecasted valuation of US$13.74 billion by the end of the period. The vaccines market is growing due to fast global developments and the commercialization of vaccines, rising rates of infectious diseases, which require preventive measures, and government initiatives to encourage vaccinations, immunization programs, advancements, and investments in new vaccines against various diseases.
- Published: October 2026
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
